Pros | - | - | ||
Cons | - | - |
INDMoney rank | - | - | ||
Category,Subcateogry | Equity,Index Funds | Equity,Index Funds | ||
Fund Age | 2 Years | 1 Years | ||
Fund Size | 95 Cr | 3496 Cr | ||
Min Investment | SIP ₹1000 Lumpsum ₹1000 | SIP ₹500 Lumpsum ₹500 | ||
Expense Ratio | 0.37% | 0.42% | ||
Exit Load | 0% | 1% | ||
Benchmark Index | Nifty Pharma TR INR | Nifty India Defence TR INR |
No of Holdings | 22 | 20 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (22.49%) Cipla Ltd (10.69%) Divi's Laboratories Ltd (10.24%) Dr Reddy's Laboratories Ltd (9.45%) Lupin Ltd (5.7%) | Hindustan Aeronautics Ltd Ordinary Shares (21.12%) Bharat Electronics Ltd (21.06%) Solar Industries India Ltd (14.62%) Mazagon Dock Shipbuilders Ltd (8.88%) Cochin Shipyard Ltd (6.32%) | ||
No of Sectors | 1 | 4 | ||
Top 3 Sectors | Health (100%) | Industrial (79.33%) Basic Materials (15.43%) Tech (4.15%) | ||
Equity % | 99.8% | 100.02% | ||
Debt % | - | - | ||
P/E | 32.3 | 49.8 | ||
P/B | 4.94 | 10.78 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -5.52% | -5% | ||
3-Month Return | 1.32% | -15.64% | ||
6-Month Return | 10.32% | 44.58% | ||
1-Year Return | -4.5% | 8.23% | ||
3-Year Return | - | - | ||
5-Year Return | - | - |
Sharpe | - | - | ||
Alpha | - | - | ||
Beta | - | - | ||
Standard Deviation | - | - | ||
Information Ratio | - | - |
Description | ICICI Prudential Nifty Pharma Index Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Motilal Oswal Nifty India Defence Index Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Ashwini Shinde,Nishit Patel | Swapnil Mayekar,Dishant Mehta,Rakesh Shetty |